Dosage ; Single doses of 5 and 10 mg.
Redosing: Doses should be separated by at least 2 hours, no more than 30mg should be taken in any 24-hour period.
The safety of treating, on average,
more than four headaches in a 30-day period has not been established.
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Imigran
NB; Not Imigram |
GlaxoSmithkline | GlaxoSmithKline | 100mg | 6 | Tablet | per tablet | KES 6,691.60 |
| Rizat | Cipla Ltd. | Lords Healthcare Ltd. | 10mg | 4 | Tablet | per tablet | KES 1,035 |
| Rizact | Cipla Ltd. | Surgipharm Ltd | 10mg | 4 | Tablet | per tablet | KES 1,200.00 |
Rizatriptan More info |
|
|---|---|
| Mode Of Action | Serotonin (5HTI) agonist |
| Drug Indication | Migraine (acute), cluster headache |
| Precautions | Renal, hepatic, neurological and CV disorders, epilepsy, sulphonamide sensitivity |
| Contra-Indications | Uncontrolled hypertension, SC use in patients with ischaemic heart disease, concomitant use with ergotamine preparations, management of hemiplegic or basilar migraine, IV use. |
| Side Effects | Burning sensation, tingling, warm/hot sensation, visual disturbances, nasal |
| Dosage | Single doses of 5 and 10 mg. Redosing: Doses should be separated by at least 2 hours, no more than 30mg should be taken in any 24-hour period. The safety of treating, on average, more than four headaches in a 30-day period has not been established. |
| Special Information | It is structurally as well as pharmacologically related to serotonin, (5-hydroxytryptamine, 5HT) differing structurally from serotonin mainly by the substitution of methane sulfonamide for the alcohol group on the indication sole ring. |
| Drug Category | DRUGS ACTING ON CNS |
| Drug Sub-Category | Anti-migraine drugs
Dosing: Adult Note: In patients with risk factors for coronary artery disease, following adequate evaluation to establish the absence of coronary artery disease, the initial dose should be administered in a setting where response may be evaluated (physician's office or similarly staffed setting). ECG monitoring may be considered. Migraine: Oral: 5-10 mg, repeat after 2 hours if significant relief is not attained; maximum: 30 mg in a 24-hour period (use 5 mg dose in patients receiving propranolol with a maximum of 15 mg in 24 hours) Note: For orally-disintegrating tablets (Maxalt-MLT®): Patient should be instructed to place tablet on tongue and allow to dissolve. Dissolved tablet will be swallowed with saliva. Dosing: Geriatric Refer to adult dosing |